The future of clinical trials in idiopathic pulmonary fibrosis
Paolo Spagnolo1, Toby M Maher2,3
1Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Purpose Of Review:
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis and limited therapeutic options. A multitude of promising compounds are currently being investigated; however, the design and conductance of late-phase clinical trials in IPF has proven particularly challenging.
Recent Findings:
Despite promising phase 2 data, ziritaxestat, an autotaxin inhibitor, pentraxin-2, an endogenous protein that regulates wound healing and fibrosis, and pamrevlumab, a human monoclonal antibody against connective tissue growth factor, failed to show efficacy in phase 3 trials. Endpoint selection is critical for the design, execution, and success of clinical trials; recently, attention has been paid to the assessment of how patients feel, function, and survive with the aim of aligning scientific objectives and patient needs in IPF. External control arms are control patients that derive from historical randomized controlled trials, registries, or electronic health records. They are increasingly used to assess treatment efficacy in clinical trials owing to their potential to reduce study duration and cost and increase generalizability of findings.
Summary:
Advances in study design, end point selection and statistical analysis, and innovative strategies for more efficient enrolment of study participants have the potential to increase the likelihood of success of late-phase clinical trials in IPF.
Insights
Late-phase clinical trials for idiopathic pulmonary fibrosis (IPF) face challenges. Improving trial design, endpoints, and recruitment strategies is key to increasing the success rate for new IPF therapies.
Area of Science:
- Pulmonary Medicine
- Fibrosis Research
- Clinical Trial Design
Background:
- Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options and a poor prognosis.
- Conducting late-phase clinical trials in IPF presents significant design and execution challenges.
- Several promising drug candidates have failed to demonstrate efficacy in Phase 3 IPF trials.
Purpose of the Study:
- To review challenges in late-phase clinical trials for idiopathic pulmonary fibrosis (IPF).
- To discuss the critical role of endpoint selection in trial success.
- To explore innovative strategies for improving the efficiency and success of IPF clinical trials.
Main Methods:
- Review of recent Phase 3 clinical trial outcomes in IPF.
- Analysis of endpoint selection, including patient-reported outcomes (PROs).
- Evaluation of the utility of external control arms in clinical trial design.
Main Results:
- Ziritaxestat, pentraxin-2, and pamrevlumab failed to show efficacy in Phase 3 IPF trials despite promising Phase 2 results.
- Endpoint selection, focusing on patient-reported outcomes (how patients feel, function, and survive), is crucial for aligning scientific goals with patient needs.
- External control arms, derived from historical data, offer potential benefits for reducing study duration, cost, and increasing generalizability.
Conclusions:
- Advances in study design, endpoint selection, and statistical analysis are vital for enhancing the success of late-phase IPF trials.
- Innovative strategies for participant enrollment can improve trial efficiency.
- A multi-faceted approach addressing design, endpoints, and recruitment is necessary to overcome challenges in IPF clinical research.
More Related Videos
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:21EPS and iPS Cells in Disease Research